Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
复制标题
DOI：
10.3892/ol.2013.1638
复制
发表时间：
2013-12
期刊：
影响因子：
2.9
通讯作者：
Wu Z
中科院分区：
文献类型：
--
作者：
Fu Y;Wei X;Tang C;Li J;Liu R;Shen A;Wu Z
循环中的微小RNA（microRNAs，miRNAs）正逐渐成为肿瘤的生物标志物，但其在B型肝炎病毒（HBV）相关肝细胞癌（HCC）中的意义尚不清楚。基于我们先前的观察，即miRNA-101（miR-101）被HBV下调并诱导表观遗传修饰，我们试图测试循环miR-101是否可以作为HCC的潜在生物标志物。实时荧光定量PCR检测miR-101在HCC和血清中的表达。在来自HBV相关HCC患者和健康对照的样本中评估组织和血清miR-101水平。miR-101表达与HCC患者的临床病理特征和预后之间也存在潜在的相关性。miR-101在HBV相关HCC组织中的表达较癌旁组织下调。此外，来自HCC患者的这些组织中的miR-101水平显著低于来自对照受试者的组织中的那些。值得注意的是，发现血清miR-101水平与组织miR-101表达水平呈负相关。血清miR-101在HBV相关性肝癌患者中的表达显著高于健康对照组，且与B表面抗原阳性、HBV DNA水平及肿瘤大小相关。这些结果表明，不同的因素支配HCC患者组织和血清中miR-101的水平。鉴于HCC患者血清miR-101水平显著且持续升高，循环miR-101可作为监测HBV相关HCC肿瘤进展的有前景的生化标志物。
Circulating microRNAs (miRNAs) are emerging as promising biomarkers for cancer; however, the significance of circulating miRNAs in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains largely unknown. Based on our prior observations that miRNA-101 (miR-101) is downregulated by HBV and induces epigenetic modification, we sought to test whether circulating miR-101 may serve as a potential biomarker for HCC. The expression of miR-101 in HCCs and serum was evaluated by real-time polymerase chain reaction. Tissue and serum miR-101 levels were assessed in samples from patients with HBV-related HCC and healthy controls. A potential correlation was also evaluated between miR-101 expression and the clinicopathological features and prognosis of HCC patients. miR-101 was downregulated in HBV-related HCC tissues compared with adjacent noncancerous tissues. Furthermore, the miR-101 levels in these tissues from HCC patients were significantly lower than those in tissues from control subjects. Notably, serum miR-101 levels were found to have an inverse correlation with tissue miR-101 expression levels. The expression of serum miR-101 in patients with HBV-related HCC was significantly higher than that in the healthy controls, and this increase correlated with hepatitis B surface antigen positivity, HBV DNA levels and tumor size. These results indicate that different factors govern the levels of miR-101 in the tissue and serum of HCC patients. Given the marked and consistent increase in serum miR-101 levels in HCC patients, circulating miR-101 may serve as a promising biochemical marker for monitoring the progression of tumor development in HBV-related HCC.
登录
查看更多内容
影响因子：
13.5
作者：
Mott, Justin L.
通讯作者：
Mott, Justin L.
影响因子：
21.3
作者：
Skog, Johan;Wuerdinger, Tom;van Rijn, Sjoerd;Meijer, Dimphna H.;Gainche, Laura;Sena-Esteves, Miguel;Curry, William T., Jr.;Carter, Bob S.;Krichevsky, Anna M.;Breakefield, Xandra O.
通讯作者：
Breakefield, Xandra O.
影响因子：
13.5
作者：
OKA, H;TAMORI, A;YAMAMOTO, S
通讯作者：
YAMAMOTO, S
DOI：
10.1073/pnas.0813371106
发表时间：
2009-03-17
影响因子：
11.1
作者：
Wang, Kai;Zhang, Shile;Galas, David J.
通讯作者：
Galas, David J.
DOI：
10.1073/pnas.0914843107
发表时间：
2010-04-06
影响因子：
11.1
作者：
Pegtel, D. Michiel;Cosmopoulos, Katherine;Middeldorp, Jaap M.
通讯作者：
Middeldorp, Jaap M.